Condition: HLA-A*0201 Positive Cells Present · Clear Cell Sarcoma (CCS) · Sponsor: Sarcoma Alliance for Research through Collaboration
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
This description comes directly from the study's public registry record.
SARC Office · (734) 930-7600 · SARC045@sarctrials.org
Always discuss trial participation with your own doctor first.
| University of Southern California - Norris Cancer Center | Los Angeles, California, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06942442